APA (7th ed.) Citation

Chakravarthy, U., Harding, S. P., Rogers, C. A., Downes, S. M., Lotery, A. J., Wordsworth, S., & Reeves, B. C. (2012). Ranibizumab versus Bevacizumab to Treat Neovascular Age-related Macular Degeneration: One-Year Findings from the IVAN Randomized Trial. Ophthalmology, 119(7), 1399. https://doi.org/10.1016/j.ophtha.2012.04.015

Chicago Style (17th ed.) Citation

Chakravarthy, Usha, Simon P. Harding, Chris A. Rogers, Susan M. Downes, Andrew J. Lotery, Sarah Wordsworth, and Barnaby C. Reeves. "Ranibizumab Versus Bevacizumab to Treat Neovascular Age-related Macular Degeneration: One-Year Findings from the IVAN Randomized Trial." Ophthalmology 119, no. 7 (2012): 1399. https://doi.org/10.1016/j.ophtha.2012.04.015.

MLA (9th ed.) Citation

Chakravarthy, Usha, et al. "Ranibizumab Versus Bevacizumab to Treat Neovascular Age-related Macular Degeneration: One-Year Findings from the IVAN Randomized Trial." Ophthalmology, vol. 119, no. 7, 2012, p. 1399, https://doi.org/10.1016/j.ophtha.2012.04.015.